Angiogenesis and anti-angiogenic strategies for glioblastomas;Angiogenèse et stratégies anti-angiogéniques des glioblastomes

Bulletin du Cancer

Volumn 92, Issue 4, 2005, Pages 360-372

  De Boüard, Sophie ^a   Guillamo, Jean Sébastien ^b  

^a UNIVERSITÉ DE CAEN   (France)

^b CHU CÔTE DE NACRE   (France)

Author keywords

Angiogenesis; Antiangiogenic therapies; Clinical trial; Glioblastoma

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; ANTISENSE OLIGONUCLEOTIDE; BETA INTERFERON; CARBOPLATIN; CARMUSTINE; CELL ADHESION MOLECULE; CILENGITIDE; CISPLATIN; ENDOSTATIN; ETOPOSIDE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FUMAGILLOL CHLOROACETYLCARBAMATE; IBUPROFEN; MARIMASTAT; METALLOPROTEINASE; MINOCYCLINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; MONOCLONAL ANTIBODY LM 609; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; PLASMINOGEN KRINGLE 1 PROTEIN; PLASMINOGEN KRINGLE 2 PROTEIN; PLASMINOGEN KRINGLE 3 PROTEIN; POLYCLONAL ANTIBODY; PROTEIN KINASE C INHIBITOR; RECEPTOR; RECEPTOR BLOCKING AGENT; RIBOZYME; SCATTER FACTOR; SEMAXANIB; SMALL NUCLEAR RNA; SQUALAMINE; SUNITINIB; SURAMIN; TEMOZOLOMIDE; THALIDOMIDE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; TUMOR NECROSIS FACTOR ALPHA; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN ANTIBODY; VITRONECTIN RECEPTOR;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL ADHESION; CLINICAL TRIAL; DRUG TARGETING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; NONHUMAN; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; BRAIN TUMOR; DRUG COMBINATION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); RAT; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BRAIN NEOPLASMS; DRUG THERAPY, COMBINATION; GLIOBLASTOMA; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; RATS;

EID: 18344388517     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
2. Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 1966; 164: 491-502.
3. Gimbrone MJ, Leapman S, Cotran R, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972; 136: 261-76.
4. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-201.
5. Asahara T, Murohara T, Sullivan A, Silver M, Van der Zee R, Li T, et al. Isolation of purative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
6. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
7. Leon S, Folkerrh R, Black P. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996; 77: 362-72.
8. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-25; [discussion: 26-9].
9. Plate K, Risau W. Angiogenesis in malignant gliomas. Glia 1995; 15: 339-47.
10. Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. J Neurooncol 2000; 50: 99-108.
11. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.
12. Minchenko A, Bauer T, Salceda S, Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 1994; 71: 374-9.
13. Plate K, Breier G, Weich H, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845-8.
14. Ikeda E, Achen M, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995; 270: 19761-6.
15. Zagzag D, Zhong H, Scalzirti J, Laughner E, Simons J, Semenza G. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000; 88: 2606-18.
16. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999; 9: 211-20.
17. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993; 4: 121-33.
18. Valter M, Wiestler O, Pietsch T. Differential control of VEGF synthesis and secretion in human glioma cells by IL-1 and EGF. Int J Dev Neurosc 1999; 17: 565-77.
19. Moriyama T, Kataoka H, Hamasuna R, Yokogami K, Uehara H, Kawano H, et al. Up-regulation of vascular endothelial growth factor induced by hepatocyte growth factor/scatter factor stimulation in human glioma cells. Biochem Biophys Res Commun 1998; 249: 73-7.
20. Dameron K, Volpert O, Tainsky M, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
21. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995; 14: 263-77.
22. Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 1997; 151: 1417-23.
23. Holash J, Maisonpierre P, Compton D, Boland P, Alexander C, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-8.
24. Zagzag D, Amirnovin R, Greco M, Yee H, Holash J, Wiegand S, et al. Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 2000; 80: 837-49.
25. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-39.
26. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61: 6624-8.
27. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2: 306-14.
28. Ke L, Fueyo J, Chen X, Steck P, Shi Y, Im S, et al. A novel approach to glioma gene therapy: down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes. Int J Oncol 1998; 12: 1391-6.
29. Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisens vascular endothelial growth factor sequence. Cancer Res 1996; 56: 393-401.
30. Ma J, Fei ZL, Klein-Szanto A, Gallo JM. Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor. Clin Exp Metastasis 1998; 16: 559-68.
31. Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, et al. Antiangiogenesis treatment for gliomas: transfer of antisens-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 1999; 59: 895-900.
32. Cheng S, Huang H, Nagane M, Ji X, Wang D, Shih C, et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996; 93: 8502-7.
33. Sasaki M, Wizigmann-Voos S, Risau W, Plare KH. Retrovirus producer cells encoding antisense VEGF prolong survival of rats with intracranial GS9L gliomas. Int J Dev Neurosci 1999; 17: 579-91.
34. Bernsen H, Rijken P, Peters J, Bakker J, Boerman R, Wesseling P, et al. Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. J Neurooncol 1998; 44: 129-36.
35. Fong T, Shawver L, Sun L, Tang C, App H, Powell T, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106.
36. Takamoto T, Sasaki M, Kuno T, Tamaki N. Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival. Kobe J Med Sci 2001; 47: 181-91.
37. Vajkoczy P, Menger MD, Vollmar B, Schilling L, Schmiedek P, Hirth KP, et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multifluorescence videomicroscopy. Neoplasia 1999; 1: 31-41.
38. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 2000; 60: 970-5.
39. Laird A, Vajkoczy P, Shawver L, Thurnher A, Liang C, Mohammadi M, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60: 4152-60.
40. O'Reilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
41. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999; 274: 29568-71.
42. Kirsch M, Strasser J, Allende R, Bello L, Zhang J, Black P. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res 1998; 58: 4654-9.
43. Joe YA, Hong YK, Chung DS, Yang YJ, Kang JK, Lee YS, et al. Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. Int J Cancer 1999; 82: 694-9.
44. Meneses PI, Abrey LE, Hajjar KA, Gultekin SH, Duvoisin RM, Berns KI, et al. Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth. Clin Cancer Res 1999; 5: 3689-94.
45. O'Reilly M, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-92.
46. Moser TL, Kenan DJ, Ashley TA, Roy JA, Goodman MD, Misra UK, et al. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci USA 2001; 98: 6656-61.
47. Graven KK, Farber HW. Endothelial hypoxic stress proteins. Kidney Int 1997; 51: 426-37.
48. Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J Biol Chem 2001; 276: 39562-8.
49. Rodolfo M, Cato EM, Soldari S, Ceruti R, Asioli M, Scanziani E, et al. Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy. Cancer Gene Ther 2001; 8: 491-6.
50. Indraccolo S, Morini M, Gola E, Carrozzino F, Habeler W, Minghelli S, et al. Effects of angiostatin gene transfer on functional properties and in vivo growth of Kaposi's sarcoma cells. Cancer Res 2001; 61: 5441-6.
51. Gyorffy S, Palmer K, Gauldie J. Adenoviral vector expressing murine angiostatin inhibits a model of breast cancer metastatic growth in the lungs of mice. Am J Pathol 2001; 159: 1137-47.
52. De Bouard S, Guillamo JS, Christov C, Lefevre N, Brugieres P, Gola E, et al. Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatin. Hum Gene Ther 2003; 14: 883-95.
53. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001; 98: 4605-10.
54. Indraccolo S, Gola E, Rosato A, Minuzzo S, Habeler W, Tisato V, et al. Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells. Gene Ther 2002; 9: 867-78.
55. O'Reilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
56. Boehm T, Folkman J, Browder T, O'Reilly M. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-7.
57. Dhanabal M, Ramchandran R, Waterman M, Lu H, Knebelmann B, Segal M, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274: 11721-6.
58. Zhang X, Wu J, Fei Z. Research of cloning, expression of human endostatin gene and its inhibition effects to the glioma in vivo. Zhonghua Yi Xue Za Zhi 2001; 81: 783-7.
59. Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF, et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 2001; 19: 35-9.
60. Read TA, Sorensen DR, Mahesparan R, Enger PO, Timpl R, Olsen BR, et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol 2001; 19: 29-34.
61. Hsu S, Volpert O, Steck P, Mikkelsen T, Polverini P, Rao S, et al. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res 1996; 56: 5684-91.
62. Iruela-Arispe M, Bornstein P, Sage H. Thrombospondin exerts an anti-angiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci USA 1991; 88: 5026-30.
63. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002; 8: 349-57.
64. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 1995; 1995: 503-6.
65. Gresser I. Antitumor effects of interferon. Acta Oncol 1989; 28: 347-53.
66. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998; 58: 2489-99.
67. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980; 208: 516-8.
68. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998; 58: 808-14.
69. Riedel F, Gotte K, Bergler W, Rojas W, Hormann K. Expression of basic fibroblast growth factor protein and its down-regulation by interferons in head and neck cancer. Head Neck 2000; 22: 183-9.
70. Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C, et al. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am J Pathol 2000; 156: 1381-93.
71. Belardelli F, Gresser I, Maury C, Duvillard P, Prade M, Maunouty MT. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. III. Inhibition of growth and necrosis of tumors implanted subcutaneously. Int J Cancer 1983; 31: 649-53.
72. Horton HM, Anderson D, Hernandez P, Barnhart KM, Norman JA, Parker SE. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci USA 1999; 96: 1553-8.
73. Iqbal Ahmed CM, Johnson DE, Demers GW, Engler H, Howe JA, Wills KN, et al. Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers. Cancer Gene Ther 2001; 8: 788-95.
74. Wiranowska M, Tresser N, Saporta S. The effect of interferon and anti-CD44 antibody on mouse glioma invasiveness in vitro. Anticancer Res 1998; 18: 3331-8.
75. Roth W, Wagenknecht B, Dichgans J, Weller M. Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells. J Neuroimmunol 1998; 87: 121-9.
76. Deb G, Donfrancesco A, Ilari I, De Sio L, Milano GM, Ghitti C, et al. Hemangioendothelioma: successful therapy with interferon-alpha: a study in Association with the Italian Pediatric Haematology/Oncology Society (AIEOP). Med Pediatr Oncol 2002; 38: 118-9.
77. Marler JJ, Rubin JB, Trede NS, Connors S, Grier H, Upton J, et al. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics 2002; 109: E37.
78. Kaban LB, Mulliken JB, Ezekowitz RA, Ebb D, Smith PS, Folkman J. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 1999; 103: 1145-9.
79. Jereb B, Petric-Grabnar G, Klun B, Lamovec J, Skrbec M, Soos E. Addition of IFN-alpha to treatment of malignant brain tumors. Acta Oncol 1994; 33: 651-4.
80. Rajkumar SV, Buckner JC, Schomberg PJ, Cascino TL, Burch PA, Dinapoli RP. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma. Int J Radiat Oncol Biol Phys 1998; 40: 297-302.
81. Buckner JC, Schomberg PJ, McGinnis WL, Cascino TL, Scheithauer BW, O'Fallon JR, et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 2001; 92: 420-33.
82. Chang SM, Barker 2nd FG, Huhn SL, Nicholas MK, Page M, Rabbitt J, et al. High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma. J Neurooncol 1998; 37: 169-76.
83. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered inrerferon-alpha. Neurology 1991; 41: 672-6.
84. Obbens EA, Feun LG, Leavens ME, Savaraj N, Stewart DJ, Gutterman JU. Phase I clinical trial of intralesional or intraventricular leukocyte interferon for intracranial malignancies. J Neurooncol 1985; 3: 61-7.
85. McKenna RM, Oberg KE. Antibodies to interferon-alpha in treated cancer patients: incidence and significance. J Interferon Cytokine Res 1997; 17: 141-3.
86. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995; 92: 4562-6.
87. Cao G, Su J, Lu W, Zhang F, Zhao G, Marteralli D, et al. Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther 2001; 8: 497-505.
88. Hong Y, Chung D, Joe Y, Yang Y, Kim K, Park Y, et al. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development. Clin Cancer Res 2000; 6: 3354-60.
89. Tanaka Y, Kawamata H, Fujimoto K, Oyasu R. Angiogenesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder. J Urol 1997; 157: 683-8.
90. Isobe N, Uozumi T, Kurisu K, Kawamoto K. Antitumor effect of TNP-470 on glial tumors transplanted in rats. Anticancer Res 1996; 16: 71-6.
91. Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza R. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurg 1994; 34: 869-75.
92. Taki T, Ohnishi T, Arita N, Hiraga S, Saitoh Y, Izumoto S, et al. Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: potent inhibition of tumor angiogenesis. J Neurooncol 1994; 19: 251-8.
93. Wilson J, Penar P. The effect of AGM-1470 in an improved intracranial 9L gliosarcoma rat model. Neurol Res 1994; 16: 121-4.
94. Devineni D, Klein-Szanto A, Gallo JM. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Res 1996; 56: 1983-7.
95. Kragh M, Spang-Thomsen M, Kristjansen PE. Time until initiation of tumor growth is an effective measure of the anti-angiogenic effect of TNP-470 on human glioblastoma in nude mice. Oncol Rep 1999; 6: 759-62.
96. Bernsen H, Rijken P, Peters H, Bakker H, Van der Kogel A. The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice. J Neurooncol 1998; 38: 51-7.
97. Brooks P, Montgomery A, Rosenfeld M, Reisfeld R, Hu T, Klier G, et al. Integrin alpha vbeta3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-64.
98. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, et al. Targered antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000; 6: 3056-61.
99. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurg 2001; 48: 151-7.
100. Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, et al. Alpha v-integrin antagonist EMD 121974 induces apoprosis in brain tumor cells growing on vitronecrin and tenascin. Int J Cancer 2002; 98: 690-7.
101. Bello L, Lucini V, Carrabba G, Giussani C, Machluf M, Pluderi TA, et al. Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. Cancer Res 2001; 61: 8730-6.
102. Abramovitch R, Dafni H, Neeman M, Nagler A, Pines M. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1999; 1: 321-9.
103. Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999; 878: 236-70.
104. Ma HI, Lin SZ, Chiang YH, Li J, Chen SL, Tsao YP, et al. Intratumoral gene therapy of malignant brain rumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Ther 2002; 9: 2-11.
105. Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001; 61: 7501-6.
106. Arrieta O, Guevara P, Reyes S, Ortiz A, Rembao D, Sotelo J. Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. Eur J Cancer 1998; 34: 2101-6.
107. Mishima K, Mazar A, Gown A, Skelly M, Ji X, Wang X, et al. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci USA 2000; 97: 8484-9.
108. Teicher B, Holden S, Ara G, Sotomayor E, Huang Z, Chen Y, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994; 57: 920-5.
109. Weingart JD, Sipos EP, Brem H. The role of minocycline in the treatment of intracranial 9L glioma. J Neurosurg 1995; 82: 635-40.
110. Staba MJ, Mauceri HJ, Kufe DW, Hallahan DE, Weichselbaum RR. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther 1998; 5: 293-300.
111. Gorski D, Mauceri H, Salloum R, Gately S, Hellman S, Beckett M, et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998; 58: 5686-9.
112. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001; 61: 39-44.
113. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394: 287-91.
114. Lund E, Bastholm L, Kristjansen P. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 2000; 6: 971-8.
115. Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001; 61: 2413-9.
116. Fine H, Figg W, Jaeckle K, Wen P, Kyritsis A, Loeffler J, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18: 708-15.
117. Steward WP, Thomas AL. Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs 2000; 9: 2913-22.
118. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-5.
119. Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizucnab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-7; Epub 2004 Jan 25.
120. Hurwitz HI, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouacil, leucovorin) as first line theray in subjects with metastatic CRC. Proc Am Soc Clin Oncol 2003: 22; [Abst. 3646].
121. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4.
122. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996; 93: 14765-70.
123. Bernsen H, Rijken P, Peters J, Bakker H, Van der Kogel A. Delayed vascular changes after antiangiogenic therapy with antivascular endothelial growth factor antibodies in human glioma xenografts in nude mice. Neurosurg 1998; 43: 570-5.
124. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209-18.
125. Millauer B, Shawver L, Plate K, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367: 576-9.
126. Machein M, Risau W, Plate K. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum Gene Ther 1999; 10: 1117-28.
127. Goldman C, Kendall R, Cabrera G, Soroceanu L, Heike Y, Gillespie G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998; 95: 8795-800.
128. Olson JJ, Polk DM, Reisner A. The efficacy and distribution of suramin in the treatment of the 9L gliosarcoma. Neurosurg 1994; 34: 297-308; [discussion: pages].
129. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, et al. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 1994; 54: 2654-60.
130. Cuevas P, Carceller F, Diaz D, Reimers D, Fernandez M, Lozano RM, et al. Abolished angiogenicity and tumorigenicity of rat glioma by 1- naphthalenemonosulfonate. Neurosci Lett 2001; 308: 185-8.
131. Stan AC, Nemati MN, Piersch T, Walter GF, Dietz H. In vivo inhibition of angiogenesis and growth of the human U-87 malignant glial tumor by treatment with an antibody against basic fibroblast growth factor. J Neurosurg 1995; 82: 1044-52.
132. Saiki M, Mima T, Takahashi JC, Tani S, Yukawa H, Ueno H, et al. Adenovirus-mediated gene transfer of a truncated form of fibroblast growth factor receptor inhibits growth of glioma cells both in vitro and in vivo. J Neurooncol 1999; 44: 195-203.
133. Auguste P, Gursel DB, Lemiere S, Reimers D, Cuevas P, Carceller F, et al. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms. Cancer Res 2001; 61: 1717-26.
134. Tanaka T, Manome Y, Wen P, Kufe D, Fine H. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997; 3: 437-42.
135. Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 2002; 16: 108-10.
136. Brockmann MA, Papadimitriou A, Brandt M, Filibrandt R, Westphal M, Lamszus K. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res 2003; 9: 4578-85.
137. Sills Jr AK, Williams JI, Tyler BM, Epstein DS, Sipos EP, Davis JD, et al. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 1998; 58: 2784-92.
138. Farrell CL, Megyesi J, Del Maestro RF. Effect of ibuprofen on tumor growth in the C6 spheroid implantation glioma model. J Neurosurg 1988; 68: 925-30.
139. Harada H, Nakagawa K, Iwata S, Saito M, Kumon Y, Sakaki S, et al. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 1999; 59: 3783-9.
140. Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P, Soria C, et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 1998; 95: 6367-72.
141. Ma HI, Guo P, Li J, Lin SZ, Chiang YH, Xiao X, et al. Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin. Cancer Res 2002; 62: 756-63.
142. Tanaka T, Cao Y, Folkman J, Fine HA. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 1998; 58: 3362-9.
143. Peroulis I, Jonas N, Saleh M. Antiangiogenic activiry of endostatin inhibits C6 glioma growth. Int J Cancer 2002; 97: 839-45.
144. Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003; 63: 8890-8.
145. Sorensen DR, Read TA, Porwol T, Olsen BR, Timpl R, Sasaki T, et al. Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma. Neurooncol 2002; 4: 1-8.
146. Saleh M, Wiegmans A, Malone Q, Stylli SS, Kaye AH. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors. J Natl Cancer Inst 1999; 91: 438-45.
147. Zhou R, Mazurchuk R, Srraubinger RM. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res 2002; 62: 2561-6.
148. Ouafik L, Sauze S, Boudouresque F, Chinot O, Delfino C, Fina F, et al. Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am J Pathol 2002; 160: 1279-92.
149. Gondi CS, Lakka SS, Yanamandra N, Siddique K, Dinh DH, Olivero WC, et al. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 2003; 22: 5967-75.
150. Lakka SS, Gondi CS, Yanamandta N, Dinh DH, Olivero WC, Gujrati M, et al. Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Res 2003; 63: 2454-61.
151. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul M. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res 2001; 7: 634-40.
152. Mauceri H, Hanna N, Beckett M, Gorski D, Staba M, Stellato K, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394: 287-91.
153. Schueneman AJ, Himmeifarb E, Geng L, Tan J, Donnelly E, Mendel D, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003; 63: 4009-16.